Equities research analysts predict that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will post earnings per share of ($0.24) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Pieris Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.14). Pieris Pharmaceuticals posted earnings of ($0.26) per share in the same quarter last year, which indicates a positive year over year growth rate of 7.7%. The business is expected to report its next quarterly earnings results on Wednesday, November 3rd.
On average, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.78) per share for the current year, with EPS estimates ranging from ($1.05) to ($0.49). For the next year, analysts expect that the firm will report earnings of ($0.79) per share, with EPS estimates ranging from ($1.10) to ($0.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, August 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.05). The company had revenue of $3.29 million during the quarter, compared to analyst estimates of $8.53 million. Pieris Pharmaceuticals had a negative net margin of 205.63% and a negative return on equity of 122.26%.
In other Pieris Pharmaceuticals news, insider Shane Olwill sold 38,400 shares of the company’s stock in a transaction on Monday, August 30th. The stock was sold at an average price of $5.11, for a total value of $196,224.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.77% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in Pieris Pharmaceuticals during the second quarter valued at $11,309,000. Point72 Asset Management L.P. bought a new stake in shares of Pieris Pharmaceuticals in the 2nd quarter valued at approximately $3,830,000. Morgan Stanley boosted its holdings in shares of Pieris Pharmaceuticals by 104.6% in the 2nd quarter. Morgan Stanley now owns 1,675,969 shares of the biotechnology company’s stock worth $6,419,000 after acquiring an additional 856,793 shares in the last quarter. EAM Investors LLC acquired a new position in Pieris Pharmaceuticals during the 2nd quarter worth $1,105,000. Finally, Ergoteles LLC acquired a new position in Pieris Pharmaceuticals during the 2nd quarter worth $796,000. Institutional investors and hedge funds own 39.92% of the company’s stock.
Shares of NASDAQ PIRS traded down $0.34 during midday trading on Thursday, reaching $5.43. 30,885 shares of the company were exchanged, compared to its average volume of 4,390,845. The stock has a market cap of $362.24 million, a P/E ratio of -6.87 and a beta of 1.19. The stock’s 50-day moving average price is $4.50 and its 200-day moving average price is $3.43. Pieris Pharmaceuticals has a one year low of $1.70 and a one year high of $6.15.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
Featured Article: Equal Weight Rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.